Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of AM-101 in Acute Inner Ear Tinnitus
NCT00860808Phase 2Completed
- Sponsor
- Altamira Therapeutics
- Start
- Mar 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esketamine in tinnitus (3 arms), sponsored by Altamira Therapeutics. Primary endpoint: Change in Minimum Masking Level at Day 90. Started Mar 2009; status: completed.
02
Drugs
esketamine
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT00860808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00860808.